An2 Therapeutics Stock Alpha and Beta Analysis
| ANTX Stock | USD 1.34 0.11 8.94% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as AN2 Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in AN2 Therapeutics over a specified time horizon. Remember, high AN2 Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to AN2 Therapeutics' market risk premium analysis include:
Beta 0.72 | Alpha 0.25 | Risk 3.63 | Sharpe Ratio 0.0749 | Expected Return 0.27 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
AN2 |
AN2 Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. AN2 Therapeutics market risk premium is the additional return an investor will receive from holding AN2 Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in AN2 Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate AN2 Therapeutics' performance over market.| α | 0.25 | β | 0.72 |
AN2 Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of AN2 Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how AN2 Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.AN2 Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how AN2 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading AN2 Therapeutics shares will generate the highest return on investment. By understating and applying AN2 Therapeutics stock market price indicators, traders can identify AN2 Therapeutics position entry and exit signals to maximize returns.
AN2 Therapeutics Return and Market Media
The median price of AN2 Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 1.06 with a coefficient of variation of 5.52. The daily time series for the period is distributed with a sample standard deviation of 0.06, arithmetic mean of 1.07, and mean deviation of 0.04. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Anthem Launches First Canadian Real Estate Development Trust IPO to Expedite Housing Availability in Metro Vancouver | 09/11/2024 |
2 | Acquisition by Day Lucy of 27500 shares of AN2 Therapeutics subject to Rule 16b-3 | 09/27/2024 |
3 | New Anthem Alert Sis N Lil Bro Drop PRIMETIME Inspired by Coach Prime of Colorado Buffaloes | 10/14/2024 |
4 | Health insurance ghost networks cost people thousands of dollars Lawsuit | 10/24/2024 |
5 | NABIP Warns of Serious Medicare Disruptions from Aetna Anthem Policy Changes, Calls for Accountability | 11/01/2024 |
6 | Insider Trading | 11/04/2024 |
7 | Poetry, Democracy, Conspiracies, and much great music at SF Leonard Cohen Festival | 11/12/2024 |
8 | AN2 Therapeutics to Participate at Upcoming Investor Conferences | 11/14/2024 |
9 | AN2 Therapeutics stock under pressure after mixed trial results limited catalysts | 11/18/2024 |
10 | Ground Media and GLAAD Win Four Anthem Awards For Groundbreaking Here We Are Campaign | 11/19/2024 |
11 | Acquisition by Readnour Robin Shane of 25000 shares of AN2 Therapeutics at 1.1548 subject to Rule 16b-3 | 11/20/2024 |
12 | AN2 Therapeutics SWOT analysis stock pivot after trial setback | 11/21/2024 |
13 | Disposition of 83337 shares by Aziz Kabeer of AN2 Therapeutics at 16.28 subject to Rule 16b-3 | 11/22/2024 |
About AN2 Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including AN2 or other stocks. Alpha measures the amount that position in AN2 Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
AN2 Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of AN2 Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AN2 Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of AN2 Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of AN2 Therapeutics. Please utilize our Beneish M Score to check the likelihood of AN2 Therapeutics' management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with AN2 Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.